ADMA BIOLOGICS, INC. (ADMA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 200M 400M 600M Q4 '11: 761K Q1 '12: 765.4K Q2 '12: 995.5K Q3 '12: 1.4M Q4 '12: 1.1M Q1 '13: 1.9M Q2 '13: 2.4M Q3 '13: 3.2M Q4 '13: 3.1M Q1 '14: 3.8M Q2 '14: 4.6M Q3 '14: 4.9M Q4 '14: 5.9M Q1 '15: 5.9M Q2 '15: 5.7M Q3 '15: 6.2M Q4 '15: 7.2M Q1 '16: 7.8M Q2 '16: 8.8M Q3 '16: 9.8M Q4 '16: 10.7M Q1 '17: 11.2M Q2 '17: 12.3M Q3 '17: 14.1M Q4 '17: 22.8M Q1 '18: 24.2M Q2 '18: 25.4M Q3 '18: 24.9M Q4 '18: 17M Q1 '19: 16.5M Q2 '19: 18.4M Q3 '19: 21.4M Q4 '19: 29.3M Q1 '20: 36M Q2 '20: 37.2M Q3 '20: 40.3M Q4 '20: 42.2M Q1 '21: 48.1M Q2 '21: 58.1M Q3 '21: 68.5M Q4 '21: 80.9M Q1 '22: 94M Q2 '22: 110.1M Q3 '22: 130.5M Q4 '22: 154.1M Q1 '23: 181.9M Q2 '23: 208.1M Q3 '23: 234.3M Q4 '23: 258.2M Q1 '24: 283.2M Q2 '24: 330.2M Q3 '24: 382.8M Q4 '24: 426.5M Q1 '25: 459.4M Q2 '25: 474.2M Q3 '25: 488.6M Q4 '25: 510.2M Q1 '26: 509.9M Q2 '26: 512.3M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Gross Profit TTM

-150M 0 150M 300M 450M Q2 '12: 643.9K Q3 '12: 859.5K Q4 '12: 449.1K Q1 '13: 710.8K Q2 '13: 880K Q3 '13: 1M Q4 '13: 1M Q1 '14: 1.4M Q2 '14: 1.7M Q3 '14: 1.8M Q4 '14: 2.2M Q1 '15: 2.2M Q2 '15: 2.1M Q3 '15: 2.4M Q4 '15: 2.9M Q1 '16: 3.1M Q2 '16: 3.5M Q3 '16: 4M Q4 '16: 4.3M Q1 '17: 4.5M Q2 '17: 2.6M Q3 '17: -5.2M Q4 '17: -6.4M Q4 '21: 1.2M Q1 '22: 6.6M Q2 '22: 15.3M Q3 '22: 24.6M Q4 '22: 35.3M Q1 '23: 48.1M Q2 '23: 57M Q3 '23: 72M Q4 '23: 88.9M Q1 '24: 111.5M Q2 '24: 152.3M Q3 '24: 187.3M Q4 '24: 219.6M Q1 '25: 241.5M Q2 '25: 251.3M Q3 '25: 267.3M Q4 '25: 292.8M Q1 '26: 312.4M Q2 '26: 331.5M Q3 '13 Q1 '15 Q3 '16 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Operating Income TTM

-80M 0 80M 160M 240M Q4 '11: -4.6M Q1 '12: -4.3M Q2 '12: -3.3M Q3 '12: -5.8M Q4 '12: -7.9M Q1 '13: -9.8M Q2 '13: -13.5M Q3 '13: -12.8M Q4 '13: -15M Q1 '14: -17.6M Q2 '14: -16.3M Q3 '14: -16.8M Q4 '14: -16M Q1 '15: -13.5M Q2 '15: -13.5M Q3 '15: -15.1M Q4 '15: -15.5M Q1 '16: -16.5M Q2 '16: -18.4M Q3 '16: -17.5M Q4 '16: -17.3M Q1 '17: -19.1M Q2 '17: -22M Q3 '17: -32.7M Q4 '17: -39.3M Q1 '18: -49.9M Q2 '18: -54.9M Q3 '18: -54.3M Q4 '18: -60.3M Q1 '19: -57M Q2 '19: -54.9M Q3 '19: -50.1M Q4 '19: -41.4M Q1 '20: -45M Q2 '20: -50.8M Q3 '20: -55.5M Q4 '20: -64.9M Q1 '21: -63.3M Q2 '21: -61.8M Q3 '21: -62.4M Q4 '21: -58.4M Q1 '22: -58M Q2 '22: -51.6M Q3 '22: -46.5M Q4 '22: -39.4M Q1 '23: -25.4M Q2 '23: -16.7M Q3 '23: 1.3M Q4 '23: 21.6M Q1 '24: 44.3M Q2 '24: 83.9M Q3 '24: 114.9M Q4 '24: 139M Q1 '25: 152M Q2 '25: 155.6M Q3 '25: 167M Q4 '25: 191.4M Q1 '26: 214.8M Q2 '26: 224.5M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-80M 0 80M 160M 240M Q2 '11: -4M Q3 '11: -5M Q4 '11: -5M Q1 '12: -4M Q2 '12: -2.8M Q3 '12: -5.1M Q4 '12: -7.3M Q1 '13: -9.9M Q2 '13: -13.6M Q3 '13: -13.1M Q4 '13: -15.5M Q1 '14: -18.2M Q2 '14: -17.3M Q3 '14: -18M Q4 '14: -16.8M Q1 '15: -14.5M Q2 '15: -15.2M Q3 '15: -17M Q4 '15: -18M Q1 '16: -19M Q2 '16: -20.3M Q3 '16: -19.5M Q4 '16: -19.5M Q1 '17: -21.4M Q2 '17: -24.5M Q3 '17: -35.3M Q4 '17: -43.8M Q1 '18: -55M Q2 '18: -60.8M Q3 '18: -60.7M Q4 '18: -65.7M Q1 '19: -61M Q2 '19: -59.5M Q3 '19: -55.8M Q4 '19: -48.3M Q1 '20: -54.5M Q2 '20: -61.4M Q3 '20: -66.9M Q4 '20: -75.7M Q1 '21: -74.9M Q2 '21: -73.6M Q3 '21: -74.4M Q4 '21: -71.6M Q1 '22: -78.3M Q2 '22: -73.1M Q3 '22: -70.3M Q4 '22: -65.9M Q1 '23: -47.7M Q2 '23: -40.3M Q3 '23: -22.8M Q4 '23: -28.2M Q1 '24: -3.6M Q2 '24: 34.8M Q3 '24: 68.1M Q4 '24: 197.7M Q1 '25: 206.8M Q2 '25: 208.9M Q3 '25: 209.4M Q4 '25: 146.9M Q1 '26: 165.4M Q2 '26: 169M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

0 80M 160M 240M Q4 '16: 1.6M Q1 '17: 1.3M Q2 '17: 5.2M Q3 '17: 16.2M Q4 '17: 27.7M Q1 '18: 39.8M Q2 '18: 45.1M Q3 '18: 43M Q4 '18: 42.2M Q1 '19: 39.4M Q2 '19: 40.2M Q3 '19: 39M Q4 '19: 39.5M Q1 '20: 46.9M Q2 '20: 49.9M Q3 '20: 53.9M Q4 '20: 61.3M Q1 '21: 62.2M Q2 '21: 67.6M Q3 '21: 76M Q4 '21: 79.8M Q1 '22: 87.4M Q2 '22: 94.7M Q3 '22: 105.9M Q4 '22: 118.8M Q1 '23: 133.8M Q2 '23: 151.1M Q3 '23: 162.3M Q4 '23: 169.3M Q1 '24: 171.6M Q2 '24: 177.9M Q3 '24: 195.5M Q4 '24: 206.9M Q1 '25: 217.8M Q2 '25: 222.9M Q3 '25: 221.3M Q4 '25: 217.4M Q1 '26: 197.4M Q2 '26: 180.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q2 '11: -1M Q3 '11: -1M Q4 '11: -1M Q1 '12: -2.6M Q2 '12: -3.1M Q3 '12: -5.1M Q4 '12: -6.9M Q1 '13: -8M Q2 '13: -9.6M Q3 '13: -9.7M Q4 '13: -10.9M Q1 '14: -12.9M Q2 '14: -14.5M Q3 '14: -14.8M Q4 '14: -14.7M Q1 '15: -13.9M Q2 '15: -14M Q3 '15: -14.2M Q4 '15: -15.4M Q1 '16: -16.4M Q2 '16: -16.7M Q3 '16: -18.7M Q4 '16: -18.3M Q1 '17: -18.5M Q2 '17: -22.5M Q3 '17: -27.5M Q4 '17: -37.3M Q1 '18: -48.3M Q2 '18: -54.4M Q3 '18: -57.2M Q4 '18: -62.7M Q1 '19: -60.5M Q2 '19: -64.2M Q3 '19: -75.3M Q4 '19: -76.2M Q1 '20: -86.6M Q2 '20: -89.2M Q3 '20: -89.4M Q4 '20: -102M Q1 '21: -110.6M Q2 '21: -121.6M Q3 '21: -111.1M Q4 '21: -112.4M Q1 '22: -105.2M Q2 '22: -85.7M Q3 '22: -85.6M Q4 '22: -59.5M Q1 '23: -48.2M Q2 '23: -41.4M Q3 '23: -16.2M Q4 '23: 8.8M Q1 '24: 21.3M Q2 '24: 73M Q3 '24: 86.1M Q4 '24: 118.7M Q1 '25: 101.2M Q2 '25: 76.7M Q3 '25: 65M Q4 '25: 50.4M Q1 '26: 128.3M Q2 '26: 136.7M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '12: -5.2M Q4 '12: -7M Q1 '13: -8.2M Q2 '13: -9.8M Q3 '13: -10M Q4 '13: -11.1M Q1 '14: -13.1M Q2 '14: -14.9M Q3 '14: -16.5M Q4 '14: -17M Q1 '15: -16.1M Q2 '15: -16M Q3 '15: -14.8M Q4 '16: -18.3M Q1 '17: -18.6M Q2 '17: -22.6M Q3 '17: -28.2M Q4 '17: -39.9M Q1 '18: -51.5M Q2 '18: -58.1M Q3 '18: -60.5M Q4 '18: -64.8M Q1 '19: -62.2M Q2 '19: -65.1M Q3 '19: -78.4M Q4 '19: -80M Q1 '20: -92.3M Q2 '20: -99.5M Q3 '20: -100.2M Q4 '20: -114.7M Q1 '21: -123.8M Q2 '21: -135.1M Q3 '21: -124.6M Q4 '21: -125.9M Q1 '22: -118.9M Q2 '22: -99M Q3 '22: -99.4M Q4 '22: -73.4M Q1 '23: -61.2M Q2 '23: -51.4M Q3 '23: -23.5M Q4 '23: 4M Q1 '24: 16.1M Q2 '24: 66.6M Q3 '24: 79.4M Q4 '24: 110.4M Q1 '25: 90.6M Q2 '25: 65.8M Q3 '25: 40.7M Q4 '25: 27.8M Q1 '26: 107.9M Q2 '26: 116.5M Q1 '13 Q4 '14 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 90M 180M 270M Q2 '20: 86.3M Q3 '20: 87.7M Q1 '21: 115.7M Q2 '21: 127.4M Q3 '21: 133.8M Q1 '22: 195.9M Q2 '22: 196.4M Q3 '22: 196.4M Q1 '23: 221.9M Q2 '23: 222.7M Q3 '23: 233.8M Q1 '24: 236.4M Q2 '24: 242.2M Q3 '24: 244.8M Q1 '25: 244.7M Q2 '25: 248.6M Q3 '25: 244.7M Q1 '26: 240M Q2 '26: 230.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q2 '11: -11.29 Q3 '11: -14.08 Q4 '11: -14.08 Q1 '12: -9.76 Q2 '12: -3.17 Q3 '12: -0.93 Q4 '12: -1.32 Q1 '13: -1.69 Q2 '13: -2.32 Q3 '13: -2.23 Q4 '13: -2.38 Q1 '14: -2.47 Q2 '14: -2.07 Q3 '14: -1.97 Q4 '14: -1.81 Q1 '15: -1.54 Q2 '15: -1.55 Q3 '15: -1.67 Q4 '15: -1.74 Q1 '16: -1.80 Q2 '16: -1.86 Q3 '16: -1.72 Q4 '16: -1.62 Q1 '17: -1.70 Q2 '17: -1.75 Q3 '17: -2.00 Q4 '17: -1.89 Q1 '18: -1.77 Q2 '18: -1.57 Q3 '18: -1.31 Q4 '18: -1.46 Q1 '19: -1.35 Q2 '19: -1.25 Q3 '19: -1.11 Q4 '19: -0.89 Q1 '20: -0.87 Q2 '20: -0.85 Q3 '20: -0.85 Q4 '20: -0.88 Q1 '21: -0.78 Q2 '21: -0.70 Q3 '21: -0.64 Q4 '21: -0.51 Q1 '22: -0.48 Q2 '22: -0.40 Q3 '22: -0.35 Q4 '22: -0.34 Q1 '23: -0.24 Q2 '23: -0.20 Q3 '23: -0.11 Q4 '23: -0.13 Q1 '24: -0.02 Q2 '24: 0.14 Q3 '24: 0.28 Q4 '24: 0.82 Q1 '25: 0.85 Q2 '25: 0.86 Q3 '25: 0.86 Q4 '25: 0.60 Q1 '26: 0.68 Q2 '26: 0.70 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.